Psyence Biomedical LtdNASDAQ PBM

Psyence Biomedical Ltd. is a life science biotechnology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.